|
KMID : 0894520190230020119
|
|
Development & Reproduction
2019 Volume.23 No. 2 p.119 ~ p.128
|
|
|
Synergistic Enhancement of Paclitaxel-induced Inhibition of Cell Growth by Metformin in Melanoma Cells
|
|
Ko Gi-Hyun
Kim Tae-Hyung
Ko Eun-Jeong
Park Deok-Bae
Lee Young-Ki
|
|
|
Abstract
|
|
|
|
Melanoma is one of the most aggressive and treatment-resistant malignancies. Antidiabetic drug metformin has been reported to inhibit cell proliferation and metastasis in many cancers, including melanoma. Metformin suppresses the mammalian target of rapamycin (mTOR) and our previous study showed that it also inhibits the activity of extracellular signal-regulated kinase (ERK). Paclitaxel is currently prescribed for treatment of melanoma. However, paclitaxel induced the activation of ERK/mitogen-activated protein kinase (MAPK) pathway, a cell signaling pathway implicated in cell survival and proliferation. Therefore, we reasoned that combined treatment of paclitaxel with metformin could be more effective in the suppression of cell proliferation than treatment of paclitaxel alone. Here, we investigated the combinatory effect of paclitaxel and metformin on the cell survival in SK-MEL-28 melanoma cell line. Our study shows that the combination of paclitaxel and metformin has synergistic effect on cell survival and suppresses the expression of proteins involved in cancer metastasis. These findings suggest that the combination of paclitaxel and metformin can be a possible therapeutic option for treatment of melanoma.
|
|
|
KEYWORD
|
|
|
Paclitaxel, Metformin, SK-MEL-28 melnoma cell, Cell viability, Metastasis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|